NEW YORK: Pfizer forecast more than US$50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the giant pharma company reported a more than doubling of annual profits on strong vaccine sales.
© New Straits Times Press (M) Bhd




